Literature DB >> 18596671

Activated stat-3 in melanoma.

Jane L Messina1, Hua Yu, Adam I Riker, Pamela N Munster, Richard L Jove, Adil I Daud.   

Abstract

BACKGROUND: Recent studies have demonstrated that the Src-Stat pathway may play an important role in melanoma. We examined the expression of phosphorylated Stat-3 (pStat-3), activated Stat-1 (pStat-1) and interferon alpha receptor subunit 1(IFNAR-1) in human melanocytic neoplasms.
METHODS: Compound nevi (6), dysplastic nevi (4), congenital nevi (2), primary melanoma (14), and sentinel lymph node metastasis (40) were examined. Specimens were evaluated for phospho-Stat-1 (pStat-1), phospho-Stat-3 (pStat-3), and IFNAR-1 by immunohistochemistry. Staining was scored from 1 to 3 based on a composite score that took into account both the percentage of tumor cells staining and the intensity of stained cells.
RESULTS: Normal melanocytes or benign nevi expressed little pStat-1, pStat-3, or IFNAR-1. In primary cutaneous melanoma, 6 of 14 skin biopsies showed activated Stat-3. However, in melanoma metastatic to regional lymph nodes, 16 of 26 had activated Stat-3 but only 6 of 23 had activated Stat-1. Melanoma tumors had high levels of either pStat-3 or pStat-1 but not both. All melanoma specimens but not benign melanocytes had cytoplasmic IFNAR-1 staining. An increase in Stat-3 activity was seen in melanoma but not in benign nevi or skin melanocytes. There appeared to be an inverse correlation between the levels of pStat-3 and pStat-1 in a given specimen.
CONCLUSIONS: The relationship between activated Stat-3 and biological behavior of melanocytic lesions observed in this study warrants further exploration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596671     DOI: 10.1177/107327480801500302

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  24 in total

1.  Targeting multiple key signaling pathways in melanoma using leelamine.

Authors:  Raghavendra Gowda; SubbaRao V Madhunapantula; Omer F Kuzu; Arati Sharma; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

Review 2.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

Authors:  Thomas F Gajewski; Mercedes Fuertes; Robbert Spaapen; Yan Zheng; Justin Kline
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

3.  Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling.

Authors:  Wei-Chun HuangFu; Juan Qian; Chengbao Liu; Hallgeir Rui; Serge Y Fuchs
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

4.  Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.

Authors:  Sabyasachi Bhattacharya; Hui Zheng; Christos Tzimas; Martin Carroll; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 5.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

6.  Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells.

Authors:  Lesley A Mathews; Elaine M Hurt; Xiaohu Zhang; William L Farrar
Journal:  Mol Cancer       Date:  2010-10-07       Impact factor: 27.401

7.  STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer.

Authors:  Yujuan Chen; Jing Wang; Xiaodong Wang; Xuejuan Liu; Hongjiang Li; Qing Lv; Jingqiang Zhu; Bing Wei; Ying Tang
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

8.  Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation.

Authors:  Jun Gui; Michael Gober; Xiaoping Yang; Kanstantsin V Katlinski; Christine M Marshall; Meena Sharma; Victoria P Werth; Darren P Baker; Hallgeir Rui; John T Seykora; Serge Y Fuchs
Journal:  J Invest Dermatol       Date:  2016-06-29       Impact factor: 8.551

9.  Essential role of HDAC6 in the regulation of PD-L1 in melanoma.

Authors:  Lienlaf M; Perez-Villarroel P; Knox T; Pabon M; Sahakian E; Powers J; Woan K V; Lee C; Cheng F; Deng S; Smalley K S M; Montecino M; Kozikowski A; Pinilla-Ibarz J; Sarnaik A; Seto E; Weber J; Sotomayor E M; Villagra A
Journal:  Mol Oncol       Date:  2016-01-06       Impact factor: 6.603

10.  12-O-tetradecanoylphorbol-13-acetate inhibits melanoma growth by inactivation of STAT3 through protein kinase C-activated tyrosine phosphatase(s).

Authors:  Masahiro Oka; Naoko Sumita; Masanobu Sakaguchi; Tetsushi Iwasaki; Toshinori Bito; Toshiro Kageshita; Ken-ichi Sato; Yasuo Fukami; Chikako Nishigori
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.